Refine by
Drug Interaction Articles & Analysis
26 news found
A critical aspect of drug development is understanding the interaction between drugs and biological systems, particularly for veterinary applications where species-specific responses can vary substantially. ...
This cutting-edge technology provides scientists and researchers with an innovative platform to study human organs in a way that was previously impossible, promising to accelerate drug discovery, reduce the need for animal testing and ultimately transform the future of medicine. ...
It plays a crucial role in drug design and screening, as it enables modeling and prediction of interactions between proteins and small molecules, allowing customers to better understand drug mechanisms of action and optimize candidate compounds. CD ComputaBio’s Protein-Small Molecule Docking service utilizes state-of-the-art computational ...
The HFSA Optimal Medical Therapy in Heart Failure (OMT-HF) program can help your patients achieve their best outcomes. An estimated 6.5 million Americans have heart failure (HF). This year alone another 960,000 will likely be diagnosed with this condition. Chances are several of your patients are in this group. Are they receiving the optimal medical therapy (OMT), that helps them achieve ...
The Cellworks platform uses computational biosimulation to model signaling pathways, master regulators, hallmark behaviors of cancer, and drug interactions with each patient’s unique disease network. Biosimulation stratifies treatment options according therapeutic impact and enables precision clinical trials that promises to transform the ...
Although the drugs themselves are complicated, it is urgent to develop techniques to characterize glycosylation in order to better evaluate their effects. One of the most significant post-translational modifications during protein characterization is glycosylation. It affects the drug's biological activity, serum half-life, stability, and immunogenicity, which ...
The field of protein DNA/RNA interactions is an expanding area of research. These interactions affect fundamental processes and as a result, relevant protein DNA/RNA processing complexes and their associated mechanisms provide interesting therapeutic targets to researchers. ...
LYTGOBI previously received breakthrough, orphan drug and priority review designations from the FDA. PRINCETON, N.J., September 30, 2022 – Taiho Oncology, Inc. and Taiho Pharmaceutical Co., Ltd. announced today that the U.S. Food and Drug Administration (FDA) has approved LYTGOBI® tablets for the treatment of adult patients with previously treated, ...
We know that a drug substance is usually more stable by itself than in a formulation with excipients. Inappropriate dosage forms can interact with drug substances and in worst cases can even cause drug degradation,” says the Marketing Chief of CD Formulation. ...
THOUSAND OAKS, Calif., May 12, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Otezla® (apremilast) have partnered with pop icon and entrepreneur Lance Bass, for the Double Take campaign to empower people to take action when it comes to psoriatic arthritis. As a singer, dancer and entertainer, Bass understands the importance of staying in tune with your body. Through the campaign, he has created ...
“With this landmark achievement of our first approved drug, we have taken a monumental step toward our mission of bringing transformative medicines in neuroscience to patients using our AI platform. ...
(Nasdaq: GANX) (“Gain”), a biotechnology company transforming the drug discovery paradigm with structurally targeted allosteric regulators (STARs) identified with its proprietary computational discovery platform, today presented new pre-clinical data from its Gaucher Disease (GD) program. ...
” Gain Therapeutics is leading the wave of innovation in the field of allosteric drug discovery and is one of the pioneers in the field of computational biology. ...
Neuroscience and Beyond: Harnessing Computational Technology and Allosteric Modulators to Drug the Undruggable BETHESDA, Md., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. ...
Excipients usually play important and diversified roles in drugs. They interact with the active pharmaceutical ingredients (APIs) to improve the performance of the drug, for example, to promote drug absorption, to reduce viscosity, or to enhance solubility. ...
It is a potent, selective inhibitor of VEGFRs 1, 2, and 3 with a long half-life designed to improve efficacy and tolerability. AVEO received U.S. Food and Drug Administration (FDA) approval for FOTIVDA on March 10, 2021 for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies. ...
On Thursday, a panel of WHO experts strongly recommended the janus kinase (JAK) inhibitor baricitinib, a drug owned by Eli Lilly, for patients with severe or critical COVID-19 in combination with corticosteroids. ...
It is a potent, selective inhibitor of VEGFRs 1, 2, and 3 with a long half-life designed to improve efficacy and tolerability. AVEO received U.S. Food and Drug Administration (FDA) approval for FOTIVDA on March 10, 2021 for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies. ...
Multiple controlled clinical trials and accumulated real-world data show that Aikening® has high efficacy and safety, with minimal drug interactions with commonly used drugs amongst HIV patients and high resistance barriers. ...
The results showed that with a two-drug regimen of ABT (replacing two NRTIs), patients could receive rapid and durable viral suppression for 48 weeks that is not inferior to standard second-line three-drug combination therapy. ...